Georgia Medicaid Substance Use Disorder Treatment (2026): MOUD, IOP, Residential

Substance use disorder treatment under Georgia Medicaid spans the full continuum of care from screening and brief intervention through medically managed inpatient detox, with medication-assisted treatment, residential rehabilitation, intensive outpatient programs, and recovery support services all covered for eligible members. The federal framework rests on several layered authorities: the Medicaid rehabilitation-services option authorizing community-based SUD services; the Mental Health Parity and Addiction Equity Act of 2008 requiring SUD benefits to be no more restrictive than medical-surgical benefits; the SUPPORT for Patients and Communities Act of 2018 creating the statutory IMD exception allowing time-limited residential SUD treatment in Institutions for Mental Diseases; and the Mainstreaming Addiction Treatment Act of 2022 eliminating the DEA X-waiver effective January 2023 so any DEA-registered prescriber can offer buprenorphine treatment for opioid use disorder without separate certification. Georgia operates a Section 1115 SUD IMD demonstration authorizing residential treatment in IMD settings, and a Section 1115 reentry demonstration providing time-limited pre-release Medicaid coverage including MOUD initiation for incarcerated individuals, addressing the catastrophic overdose risk in the weeks following release. This guide walks through the full benefit package, the medication options, the ASAM levels of care, the specialty populations (pregnancy, adolescents, co-occurring disorders, incarceration reentry), and the Georgia delivery system from CMOs through the DBHDD Community Service Board network.

By Brevy Care Team · Last verified May 12, 2026

The Medicaid statutory authorities

Medicaid SUD coverage rests on a stack of federal authorities under Title XIX of the Social Security Act. The most important categories are:

• Inpatient hospital services (covering hospital-based detox at ASAM Level 4)
• Outpatient hospital services (covering hospital-based outpatient SUD)
• Clinic services (covering OTPs in some state structures)
• Rehabilitative services (the rehabilitation option, the principal authority for community-based SUD services including counseling, IOP, PHP, case management, peer support, and residential treatment in non-IMD settings)
• Health home services

States have substantial flexibility in defining the rehabilitation option's scope. Georgia uses rehabilitation-option authority to cover individual and group counseling, intensive outpatient and partial hospitalization, case management, peer support, and Level 3.1 residential treatment in facilities with 16 or fewer beds. For higher-acuity residential at Levels 3.5, 3.7, and 4 in IMD settings, Georgia operates under Section 1115 demonstration authority.

The IMD exclusion and its SUD exception

Medicaid has long excluded payment for services provided to under-65 adults in Institutions for Mental Diseases (IMDs), defined as inpatient facilities with more than 16 beds primarily engaged in providing diagnosis, treatment, or care to persons with mental diseases (including SUD). The IMD exclusion was established in the original Medicaid statute, premised on the policy that state institutional care for mental illness should remain a state responsibility rather than a federal-state shared responsibility.

The exclusion has been the largest single barrier to Medicaid coverage of residential SUD treatment, because most residential SUD facilities exceed 16 beds. For decades, states either accepted the limitation, operated state-only-funded residential programs, or sought Section 1115 demonstration waivers (which CMS began approving in recent years as part of federal opioid response initiatives).

The SUPPORT for Patients and Communities Act of 2018 created the first statutory exception. The exception permits time-limited Medicaid payment for SUD treatment in IMDs; consult current CMS Section 1115 SUD IMD guidance for the operative day-limit. The exception is permissive: states must opt in by amending the state plan or operating under Section 1115. Georgia operates a Section 1115 SUD IMD demonstration that coexists with the statutory exception, authorizing ASAM Levels 3.1, 3.3, 3.5, 3.7, and 4 in IMD settings.

The Mental Health Parity and Addiction Equity Act of 2008

The Mental Health Parity and Addiction Equity Act of 2008 is the foundational federal parity law. It requires that group health plans, individual health insurance, and (added by the Affordable Care Act) Medicaid managed care organizations provide MH/SUD benefits that are no more restrictive than medical-surgical benefits across three dimensions:

Financial requirements. Deductibles, copays, coinsurance, and out-of-pocket maximums for MH/SUD benefits cannot be more restrictive than the predominant requirement for medical-surgical benefits in the same classification.

Quantitative treatment limitations. Visit limits, day limits, dollar limits, and frequency limits for MH/SUD cannot be more restrictive than those for medical-surgical benefits.

Non-quantitative treatment limitations (NQTLs). Medical necessity criteria, prior authorization, step therapy, network adequacy, provider reimbursement, and similar non-numeric limitations applied to MH/SUD benefits cannot be more restrictive in operation than those applied to medical-surgical benefits. NQTL parity is the most contested and complex aspect of parity compliance.

CMS implemented parity in Medicaid managed care through federal regulation. Georgia CMOs must perform parity analyses periodically and demonstrate compliance. Parity has been the lever for expanding SUD coverage scope, reducing prior authorization burdens, and improving network adequacy. A recent federal parity final rule strengthened NQTL compliance documentation requirements.

The SUPPORT Act of 2018

The SUPPORT for Patients and Communities Act of 2018 was the most comprehensive federal opioid response legislation in a generation. Medicaid-related provisions include:

• Former Foster Care Children Medicaid clarification: youth who aged out of foster care in any state qualify for FFCC Medicaid through age 26.
• Required Medicaid coverage of all FDA-approved medications for SUD (with delayed enforcement and ongoing implementation).
• An IMD exception authorizing time-limited Medicaid payment for SUD treatment in IMDs.
• Priority access for pregnant and postpartum women to inpatient and outpatient SUD treatment.
• SBIRT authorities for Medicaid screening, brief intervention, and referral to treatment.
• Option for states to establish SUD health homes with enhanced FMAP.

The SUPPORT Act, together with the Comprehensive Addiction and Recovery Act of 2016 and the 21st Century Cures Act of 2016 SAMHSA grants, fundamentally reshaped the federal SUD treatment landscape.

The MATE Act and X-waiver elimination

Until January 2023, physicians prescribing buprenorphine for OUD needed a special DEA registration called the "X-waiver" or DATA-waiver, created by the Drug Addiction Treatment Act of 2000 (DATA 2000). The waiver required mandatory training and limited patient panel size.

The Mainstreaming Addiction Treatment Act of 2022 (MATE Act), enacted as part of the Consolidated Appropriations Act, 2023, eliminated the X-waiver effective January 2023. Any DEA-registered prescriber with Schedule III prescribing authority can now prescribe buprenorphine for OUD without a separate waiver. The MATE Act also added a one-time SUD training requirement for all DEA registrants applicable at next registration renewal.

X-waiver elimination has dramatically expanded prescriber availability in Georgia. Primary care physicians, OB/GYNs, pediatricians (for patients age 16 and older), psychiatrists, nurse practitioners, physician assistants, and other DEA-registered prescribers can now offer office-based opioid treatment without restriction on practice setting or patient panel size.

Methadone for OUD remains OTP-only

Methadone for opioid use disorder remains restricted to licensed Opioid Treatment Programs (OTPs) under federal regulation. Methadone for chronic pain can be prescribed in any setting by any DEA-registered prescriber, but methadone for OUD requires:

• Daily observed dosing at an OTP (with progressive take-home privileges)
• Federal OTP licensure
• DEA registration of the OTP
• SAMHSA certification
• State licensure (DBHDD in Georgia)

Georgia has multiple SAMHSA-certified OTPs concentrated in metro Atlanta with sparser rural coverage; check the SAMHSA OTP Directory for the current count and locations. SAMHSA's recent final rule revising the federal OTP regulations expanded methadone take-home privileges: stable patients can now receive substantially longer take-home supplies, and audio-only telehealth is permitted for methadone counseling.

CCBHC and the integrated care model

The Excellence in Mental Health Act of 2014 authorized the Certified Community Behavioral Health Clinic (CCBHC) demonstration. CCBHCs are integrated behavioral health clinics that provide:

• 24/7 mobile crisis services
• Comprehensive screening and assessment
• Outpatient mental health and SUD treatment
• Targeted case management
• Psychiatric rehabilitation
• Peer support
• Community-based mental health care for veterans

CCBHCs receive enhanced Medicaid reimbursement on a cost-based prospective payment system. The Bipartisan Safer Communities Act of 2022 expanded the demonstration and made it permanent in participating states. Georgia operates CCBHCs in select counties with statewide expansion underway.

Section 1115 reentry demonstrations

CMS has approved Section 1115 reentry demonstrations in recent years for several states. The demonstration provides time-limited pre-release Medicaid coverage to incarcerated individuals before scheduled release. Georgia received CMS approval for a pre-release coverage demonstration; consult the CMS Section 1115 demonstrations page and the Georgia DCH page for current approval terms and day-limits. Covered services include case management, behavioral health and SUD assessment, MOUD initiation or continuation, hepatitis C treatment, HIV treatment, chronic disease medication management, and care coordination with community providers post-release.

The reentry demonstration addresses one of the highest-impact intervention points in SUD treatment. Research repeatedly shows that the weeks immediately after release from incarceration carry a dramatically elevated risk of overdose death compared to the general population, driven by reduced opioid tolerance during incarceration and continued availability post-release. Initiating or continuing MOUD before release substantially reduces this risk. Implementation in Georgia is phased in partnership with the Georgia Department of Corrections, the Georgia Department of Juvenile Justice, county jails, and DCH.

42 CFR Part 2 confidentiality

Federal SUD treatment records receive heightened confidentiality protection under 42 CFR Part 2. Part 2 applies to "Part 2 programs," meaning federally assisted SUD treatment programs that hold themselves out as providing SUD services. Part 2 is stricter than HIPAA in several ways:

• Disclosure requires specific written consent (more granular than HIPAA)
• Re-disclosure prohibited unless original consent permits
• Court orders required for law enforcement disclosure
• Limited exceptions for medical emergency, qualified service organizations, and research

The CARES Act of 2020 directed alignment of Part 2 with HIPAA for treatment, payment, and operations purposes. HHS finalized aligning rules in a 2024 final rule, easing some Part 2 restrictions while preserving the core confidentiality framework. Georgia Part 2 programs must continue to obtain specific patient consent for SUD record disclosures outside the limited exceptions.

Naloxone access

Naloxone is the opioid overdose reversal medication. Federal and state policy has progressively expanded access:

• State naloxone access laws authorize lay administration
• SAMHSA naloxone distribution program grants
• Georgia issued a statewide naloxone standing order through DPH
• FDA approved over-the-counter Narcan nasal spray in 2023
• FDA approved RiVive (a second OTC naloxone product) in 2024

Georgia Medicaid covers naloxone without prior authorization at no out-of-pocket cost. The DPH standing order allows pharmacists to dispense naloxone without an individual prescription. Naloxone is also available through community organizations, first responders, harm reduction programs, and any retail pharmacy as OTC.

Georgia substance use disorder treatment delivery system

DBHDD as the state authority

The Georgia Department of Behavioral Health and Developmental Disabilities (DBHDD) is the single state authority for behavioral health under Georgia law. DBHDD operates:

• State-funded behavioral health services for uninsured Georgians
• The Community Service Board (CSB) network serving communities across Georgia
• The Georgia Crisis and Access Line (GCAL) at 1-800-715-4225
• Crisis Stabilization Units (CSUs) and Behavioral Health Crisis Centers (BHCCs)
• State psychiatric hospitals
• OTP licensure and oversight
• Provider certification and licensure
• IDD waiver administration (NOW and COMP)

Community Service Boards

Georgia's Community Service Boards are county-operated or multi-county behavioral health authorities established under Georgia law. They provide outpatient mental health and SUD services on a sliding fee scale for uninsured patients and accept Medicaid for enrolled members. CSBs are the most common entry point for SUD treatment for low-income Georgians. Most CSBs offer outpatient SUD counseling, intensive outpatient programs, MOUD prescribing (especially post-X-waiver elimination), co-occurring disorders treatment, peer support, residential treatment linkage, and crisis services.

CMO behavioral health structure

The four Georgia CMOs (Amerigroup, Peach State, CareSource, WellCare) cover behavioral health for enrolled members. Behavioral health is "carved in" to the CMOs, meaning utilization management, prior authorization, provider credentialing, and claims payment are handled by the CMO rather than carved out to a behavioral health vendor. Each CMO maintains a behavioral health provider network and care management capability. All four CMOs cover the full ASAM continuum subject to medical necessity criteria.

For services beyond the Medicaid benefit package (residential treatment longer than the 30-day IMD exception, services for uninsured family members, recovery support not covered by Medicaid), DBHDD-funded wraparound services fill the gap.

Pathways to Coverage and SUD

Georgia Pathways to Coverage, approved under Section 1115 in 2023, provides Medicaid coverage to adults under the program's income threshold with a work requirement. SUD treatment is one of the qualifying activities that satisfies the work requirement: enrollment in a structured SUD treatment program at the required monthly hours counts as qualifying activity. Pathways enrollees receive the full Medicaid benefit package including SUD treatment.

Pathways has enrolled fewer Georgians than initial projections, with administrative burden from monthly reporting being the principal barrier. For Georgians with SUD who would otherwise be uninsured, Pathways is the most accessible Medicaid pathway, with SUD treatment participation serving the dual function of treatment and Medicaid maintenance.

Crisis services

Georgia crisis services have been substantially restructured in recent years, with continuing investment driven by the 988 Suicide and Crisis Lifeline launch in 2022 and the Bipartisan Safer Communities Act crisis services funding.

GCAL at 1-800-715-4225 is the 24/7 crisis line operated by DBHDD. It provides assessment, triage, linkage to mobile crisis teams, linkage to CSUs and inpatient psychiatric beds, and linkage to outpatient services. Georgia 988 calls route to GCAL.

Mobile crisis teams operated by CSBs respond to community locations (homes, schools, workplaces, public spaces) to provide on-site crisis stabilization. They can de-escalate, transport to higher-level care, arrange follow-up, and coordinate with law enforcement under alternative-response protocols.

Crisis Stabilization Units (CSUs) are 16-bed or smaller short-term residential facilities providing 3-5 day crisis stabilization. CSUs accept walk-ins, law enforcement drop-offs, and mobile crisis referrals.

Behavioral Health Crisis Centers (BHCCs) are the newer integrated model combining 23-hour observation, CSU beds, and outpatient services on a single campus. Georgia is expanding BHCCs as the preferred crisis service model.

The ASAM continuum of care

The American Society of Addiction Medicine (ASAM) Criteria provides the standardized framework for matching patients to appropriate SUD treatment intensity. Georgia Medicaid uses ASAM Criteria as the medical necessity framework. Six dimensions are assessed: acute intoxication and withdrawal potential; biomedical conditions; emotional/behavioral/cognitive conditions; readiness to change; relapse potential; and recovery environment.

Level 0.5: Early Intervention. Screening, Brief Intervention, and Referral to Treatment (SBIRT) for individuals at risk but not yet meeting full SUD criteria. Delivered in primary care, emergency departments, OB visits, schools. Reimbursed under HCPCS codes for SBIRT.

Level 1: Outpatient Treatment. Less than 9 hours per week of structured services. Individual therapy, group therapy, family therapy, relapse prevention, MOUD prescribing in OBOT settings, psychoeducation, recovery support coordination. The most common level of SUD treatment in Georgia.

Level 2.1: Intensive Outpatient (IOP). 9 to 19 hours per week of structured group and individual sessions, typically 3 days per week for 3-4 hours per session. Patient lives at home. Used as step-down from residential or as more intensive than outpatient when home environment is stable.

Level 2.5: Partial Hospitalization Program (PHP). 20 or more hours per week of structured day treatment, typically 5 days per week. Patient lives at home or in recovery housing. Used for acute stabilization without 24/7 medical supervision, step-down from residential, or high-intensity outpatient for severe SUD.

Level 3.1: Clinically Managed Low-Intensity Residential. 24-hour residential setting with weekly clinical contact. "Halfway house" or recovery residence. Focused on relapse prevention and reintegration.

Level 3.3: Clinically Managed Population-Specific High-Intensity Residential. 24-hour residential designed for older adults, persons with cognitive impairment, or other special populations.

Level 3.5: Clinically Managed High-Intensity Residential. 24-hour residential with daily clinical contact. Frequently 28-30 day programs. Covered under Georgia's 1115 IMD demo.

Level 3.7: Medically Monitored Intensive Inpatient. 24-hour residential with 24-hour nursing and access to physician services. Includes medically monitored withdrawal management (detox). Often "inpatient rehab" colloquially. Covered under Georgia's 1115 IMD demo.

Level 4: Medically Managed Intensive Inpatient. Hospital-based detox and intensive treatment with 24-hour physician and nursing. For severe withdrawal (alcohol with seizures, benzodiazepine withdrawal, opioid withdrawal with medical complications) or co-occurring medical instability.

OTP: Opioid Treatment Programs. Specialized programs licensed under 42 CFR 8 providing methadone (and increasingly buprenorphine) for OUD. Daily observed dosing initially with progressive take-home privileges.

OBOT: Office-Based Opioid Treatment. Buprenorphine prescribing in outpatient settings: primary care, OB/GYN, psychiatry, FQHC, CSB. Post-X-waiver elimination, any DEA-registered prescriber can offer OBOT.

Medications for Opioid Use Disorder

Buprenorphine

Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it substantially safer in overdose than full agonists. FDA-approved in 2002 in the United States. Forms covered by Georgia Medicaid:

• Buprenorphine/naloxone sublingual film (Suboxone and generics). Most common form. Preferred on Georgia PDL.
• Buprenorphine/naloxone sublingual tablet (Zubsolv and generics). Alternative formulation.
• Buprenorphine sublingual tablet (Subutex). Buprenorphine monotherapy without naloxone. Used in pregnancy (historically preferred), in patients with naloxone hypersensitivity, and in some other clinical scenarios.
• Buprenorphine extended-release subcutaneous injection (Sublocade). Monthly injection administered in the clinic. Indicated for patients who have completed at least 7 days of sublingual buprenorphine. Covered with prior authorization documenting stable sublingual response.
• Buprenorphine subdermal implant (Probuphine). Six-month implant. Less commonly used.

Coverage details: Georgia Medicaid PDL covers Suboxone film as preferred without prior authorization. Sublocade requires PA documenting sublingual stabilization (though clinical exceptions are available for patients with injection drug use history where injectable from the start is preferable). Generics are widely covered. Copays are $0 for the populations exempt from cost-sharing (children, pregnant women, LTC residents, family planning enrollees) and nominal for others; verify current dollar amounts in the DCH Member Handbook.

Telehealth buprenorphine is permanent under DEA's 2024 final rule. Audio-video telehealth is permitted for initiation; audio-only is permitted for maintenance of established patients.

Methadone

Methadone is a full mu-opioid agonist that provides 24-hour relief of withdrawal and craving. It is the longest-established MOUD, in use for OUD since the 1960s. Methadone for OUD is restricted to licensed OTPs under 42 CFR 8 and 42 CFR 1306.07. Daily observed dosing is required initially, with progressive take-home privileges as patients demonstrate stability.

SAMHSA's recent revision to the federal OTP regulations substantially expanded take-home privileges. Stable patients can now receive substantially longer take-home supplies than under the prior rule. The first month requires daily dosing, but patients can graduate to less frequent visits as they demonstrate stability. Consult the current SAMHSA OTP guidance for the operative take-home schedule. Audio-only telehealth is permitted for counseling.

Coverage: Methadone for OUD is paid through OTP global rates under Medicaid (the OTP receives a daily or weekly bundled payment that covers methadone, counseling, drug testing, and other OTP services). The patient does not have a pharmacy copay because methadone is not dispensed through retail pharmacy for OUD.

OTP access in Georgia is geographically uneven. Metro Atlanta has the highest concentration; rural Georgia has limited OTP availability. The recent take-home expansion partially addresses access barriers by reducing the need for daily on-site presence.

Extended-release naltrexone (Vivitrol)

Vivitrol is an opioid antagonist administered as a monthly intramuscular injection. It blocks opioid receptors, preventing both the euphoric effects and the relief of withdrawal that would otherwise be provided by opioids. Initiation requires a 7-10 day opioid-free period (or 4 days for short-acting opioids) to avoid precipitated withdrawal. This requirement is the primary barrier to initiation; patients must successfully complete detox before starting Vivitrol.

Coverage: Vivitrol is covered through medical benefit (administered in clinic) or pharmacy benefit (specialty pharmacy ships to clinic for administration). Either way, the patient sees the medication administered rather than dispensed for self-administration. PA is required.

Choosing among MOUD options

The three MOUD options have overlapping but distinct profiles:

• Buprenorphine offers the broadest accessibility (any prescriber, retail pharmacy dispensing, home self-administration), the strongest safety profile (ceiling effect), and the most flexibility. Disadvantage: requires daily dosing (sublingual) or monthly visits (Sublocade).
• Methadone offers the strongest evidence for severe OUD and for patients who have not responded to buprenorphine. Disadvantage: OTP-only, geographic access barriers, requires substantial commitment to OTP visits.
• Vivitrol offers complete opioid blockade for patients committed to abstinence. Disadvantage: requires opioid-free initiation, monthly clinic visits, and is less effective at retention than buprenorphine or methadone.

ASAM, NIDA, and SAMHSA all consider buprenorphine and methadone first-line, with Vivitrol second-line. Patient preference should drive selection within the clinically appropriate options.

Medications for Alcohol Use Disorder

Several FDA-approved medications are covered by Georgia Medicaid for alcohol use disorder:

Naltrexone. Oral (50mg daily) or extended-release injection (Vivitrol 380mg monthly). Reduces craving and the rewarding effects of alcohol. Effective in moderate to severe AUD.

Acamprosate (Campral). 666mg three times daily oral. Maintains abstinence after detoxification by modulating glutamate and GABA neurotransmission. Best evidence in patients who have completed detox and are motivated to remain abstinent.

Disulfiram (Antabuse). Produces an aversive reaction (nausea, vomiting, flushing) with alcohol consumption by inhibiting aldehyde dehydrogenase. Requires patient motivation and ideally supervised administration (some patients have a family member or pharmacist dispense daily).

Off-label medications. Topiramate, gabapentin, baclofen, and ondansetron are sometimes used for AUD; coverage is variable and may require PA documenting failure of FDA-approved medications.

Pregnancy and SUD

The SUPPORT Act prioritized SUD treatment for pregnant and postpartum women, providing Medicaid coverage of inpatient and outpatient SUD treatment without IMD restriction during pregnancy and the postpartum coverage period.

ACOG, SAMHSA, and NIDA all recommend MOUD continuation or initiation in pregnancy. Untreated OUD during pregnancy carries higher risk than MOUD: preterm delivery, fetal demise, maternal overdose. The risk-benefit balance strongly favors treatment.

Subutex (buprenorphine monotherapy) was historically preferred over Suboxone (buprenorphine/naloxone) in pregnancy due to theoretical concerns about naloxone effects, though current evidence supports either formulation as safe in pregnancy. Methadone is an alternative with longer historical use in pregnancy and is preferred for some patients (very severe OUD, history of buprenorphine non-response). The Pregnant Postpartum and Other Specialty Care (POSC) program at DBHDD provides intensive case management for pregnant women with SUD.

Neonatal Abstinence Syndrome (NAS, also called Neonatal Opioid Withdrawal Syndrome, NOWS) occurs in infants exposed to opioids in utero. Treatment includes the Eat, Sleep, Console (ESC) model (non-pharmacologic-first), morphine or methadone if pharmacologic intervention needed, rooming-in with mother, and breastfeeding (encouraged if mother is on stable MOUD).

The Comprehensive Addiction and Recovery Act of 2016 (CARA) required states to develop Plans of Safe Care for substance-exposed newborns. Georgia DBHDD operates the POSC program with linkages to Pregnancy Medicaid SUD treatment, Healthy Start Georgia, and Nurse-Family Partnership home visiting. Importantly, POSC does not equate to mandated DFCS referral; the program is designed as a support framework rather than a child welfare trigger.

The American Rescue Plan Act of 2021 extended pregnancy Medicaid postpartum coverage from a short post-pregnancy window to 12 months. Georgia adopted the 12-month extension via state plan amendment.

Adolescent SUD

Buprenorphine is FDA-approved for age 16 and older. Off-label use in younger adolescents requires careful clinical judgment. Naltrexone (oral and injectable) is approved for ages 18 and older; off-label adolescent use occurs. Methadone for OUD in adolescents under 18 requires documented prior detox attempts and specific OTP authorization, per federal OTP regulations.

Adolescent-specific SUD treatment programs in Georgia operate through DBHDD's Adolescent Treatment Network. Services include outpatient counseling, IOP, adolescent residential SUD treatment (multiple programs statewide), co-occurring MH+SUD integrated treatment, family-involved therapy, school-based prevention and intervention, and recovery high schools (limited but expanding).

Confidentiality for adolescent SUD treatment is governed by 42 CFR Part 2 and Georgia minor consent law, which allows minors age 12 and older to consent to their own SUD treatment without parental notification. The interplay between federal Part 2 and state minor consent is complex but generally protective of adolescent confidentiality.

Recovery support services

Beyond clinical treatment, Georgia Medicaid covers recovery support services that aid long-term recovery.

Certified Addiction Recovery Empowerment Specialist (CARES). Georgia's peer support credential for individuals in long-term recovery who provide non-clinical support to others in early or sustained recovery. CARES services are Medicaid-reimbursable through DBHDD CSBs and contracted providers.

Recovery housing. Oxford Houses (peer-led sober living) and licensed recovery residences provide supportive housing for individuals in recovery. Medicaid does not directly pay for rent in recovery housing (which is the patient's responsibility), but Medicaid covers the clinical services patients receive while in recovery housing.

Vocational rehabilitation. Georgia Vocational Rehabilitation Agency (GVRA) provides services for people with disabilities including SUD-related disability. Coordination between SUD treatment and GVRA supports employment outcomes.

Recovery community organizations (RCOs). Georgia has RCOs in multiple regions providing peer support, education, advocacy, and recovery support services. RCOs often serve as a bridge between formal treatment and long-term recovery, providing community connection that reduces isolation and relapse risk.

Crisis services

Georgia crisis services have been restructured around the 988 launch and Bipartisan Safer Communities Act 2022 investment.

Georgia Crisis and Access Line (GCAL) at 1-800-715-4225 is the 24/7 crisis hotline operated by DBHDD. GCAL provides crisis assessment and triage, mobile crisis team dispatch, CSU bed location, inpatient psychiatric bed location, outpatient linkage, and SUD treatment linkage. Georgia 988 calls route to GCAL.

988 Suicide and Crisis Lifeline. Three-digit dialing implemented July 2022 federally. Georgia callers reach GCAL. Text and chat options available.

Mobile crisis teams operated by CSBs respond to community locations. They de-escalate, transport to higher-level care, arrange follow-up, and coordinate with law enforcement under alternative-response protocols.

Crisis Stabilization Units (CSUs) are short-term (3-5 day) residential facilities for crisis stabilization with 16 or fewer beds (to avoid IMD restriction). CSUs accept walk-ins, law enforcement drop-offs, and mobile crisis referrals.

Behavioral Health Crisis Centers (BHCCs) combine 23-hour observation, CSU beds, and outpatient services on a single campus. Georgia is expanding BHCCs as the preferred crisis service model, providing a community-based alternative to emergency departments for behavioral health crisis.

Section 1115 reentry: pre-release MOUD

Georgia's Section 1115 reentry demonstration approved by CMS provides time-limited pre-release Medicaid coverage to incarcerated individuals scheduled for release. Covered services include case management and care coordination, behavioral health and SUD assessment, MOUD initiation or continuation (Suboxone, methadone via OTP, Vivitrol), hepatitis C treatment, HIV treatment, chronic disease medication management, and discharge planning to community providers.

The reentry demonstration addresses the highest-risk period for post-release overdose. Research consistently shows that the weeks immediately after release from incarceration carry a dramatically elevated risk of overdose death compared to the general population. Reduced opioid tolerance during incarceration combined with continued availability post-release drives this risk. Initiating or continuing MOUD before release substantially reduces overdose mortality.

Georgia Department of Corrections, Georgia Department of Juvenile Justice, Georgia county jails, and DCH are collaborating on implementation. Initial focus is on individuals with documented OUD; rollout is phased and will expand to other populations and conditions.

Fifteen things commonly missed

1. The X-waiver was eliminated January 2023. Any DEA-registered prescriber can prescribe buprenorphine for OUD without separate certification. Primary care, OB/GYN, NPs, PAs all qualify.
2. The statutory IMD exception allows time-limited residential SUD treatment in IMDs. Georgia operates under both the statutory exception and a Section 1115 demonstration covering ASAM Levels 3.1 through 4.
3. Georgia's Section 1115 reentry demonstration provides pre-release Medicaid coverage including MOUD initiation. Implementation is phased; consult DCH for the current covered population and effective date.
4. Naloxone is covered without prior authorization at no out-of-pocket cost. It is also available OTC at any retail pharmacy.
5. 42 CFR Part 2 confidentiality is stricter than HIPAA. Specific written consent required for disclosure; the recent final rule aligned Part 2 with HIPAA for treatment/payment/operations.
6. Methadone for OUD is OTP-only. Methadone for chronic pain can be prescribed in any setting, but OUD prescribing requires daily observed dosing at a licensed OTP.
7. Buprenorphine is available through OBOT in any clinical setting. Primary care, FQHC, CSB, OB/GYN, psychiatry, urgent care.
8. SAMHSA's recent OTP rule substantially expanded methadone take-home privileges. This improves access for patients in stable maintenance.
9. Pregnant women receive priority SUD treatment. Pregnancy Medicaid covers SUD treatment throughout pregnancy and 12 months postpartum (ARPA extension).
10. Plan of Safe Care (POSC) for substance-exposed newborns is not equivalent to DFCS referral. POSC is a support framework; child welfare involvement depends on safety assessment.
11. Adolescents 12 and older can consent to their own SUD treatment in Georgia. Georgia minor consent law establishes minor consent for SUD treatment.
12. Pathways to Coverage treats SUD treatment participation as qualifying activity for the work requirement. Treatment program participation meeting the monthly-hours threshold satisfies the requirement.
13. CCBHCs receive enhanced cost-based Medicaid reimbursement for integrated MH+SUD care. Georgia is expanding CCBHC capacity.
14. Telehealth buprenorphine is permanent under DEA's recent final rule. Audio-video for initiation; audio-only for maintenance of established patients.
15. MHPAEA parity applies to NQTLs. Medical necessity criteria, prior authorization, and network adequacy for SUD must be no more restrictive than for medical-surgical benefits.

Worked examples

Larry, 41, Columbus: Pathways enrollment + OBOT + IOP

Larry has been in and out of opioid use for many years, with multiple overdoses and incarcerations. He enrolled in Pathways to Coverage when his SSI application was denied. His Pathways enrollment qualified him for full Medicaid. He started buprenorphine/naloxone (Suboxone film) with a primary care physician at his local CSB who began offering OBOT after X-waiver elimination. He attends IOP three times per week at the CSB (group therapy plus individual sessions). He has a CARES peer support specialist who meets with him weekly. His SUD treatment participation satisfies the Pathways work requirement. He has a naloxone kit at home. His prescription copays are minimal. After six months of stability with continuous negative urine drug screens, he is discussing with his clinical team reducing IOP to once-weekly outpatient counseling while maintaining buprenorphine.

Marcus, 32, Atlanta: Methadone maintenance + integrated MH care at CCBHC

Marcus has been on methadone maintenance for several years at an Atlanta OTP. His ABD Medicaid covers OTP services through the global rate paid to the OTP. He picked up his methadone daily for the first stretch of treatment, then progressed to weekly take-home, then longer take-home windows, and under the recent SAMHSA rules to the longest take-home interval permitted for stable patients. He has co-occurring major depressive disorder treated with sertraline and weekly therapy. His treatment is now coordinated through a CCBHC in southeast Atlanta that provides integrated MH and SUD care, with his OTP communicating regularly with the CCBHC clinical team via written Part 2 consent. He has been employed continuously for several years.

Sarah, 28, Macon: Pregnancy MAT + POSC + 12-month postpartum

Sarah presented to OB in the second trimester with active heroin use. She was started on buprenorphine monotherapy (Subutex) under joint OB/MAT prescriber care. Her Pregnancy Medicaid covers all care. She is enrolled in DBHDD's Pregnant Postpartum and Specialty Care (POSC) program with intensive case management. Healthy Start Georgia provides additional support including home visiting. At delivery, her newborn was managed with the Eat, Sleep, Console model and required only minimal pharmacologic intervention for NAS symptoms over a brief NICU stay. She is breastfeeding. Her postpartum Medicaid covers 12 months under the ARPA extension. She continues Subutex postpartum with a planned slow taper. POSC continues to support her transition to community-based treatment.

Tyrell, 17, Savannah: Adolescent OUD + buprenorphine age 16+ + foster care plan

Tyrell is in foster care (Amerigroup Foster Care Plan / Georgia Families 360) and developed opioid use disorder after a sports injury and resulting oxycodone prescription. He was assessed by an adolescent SUD specialist who started buprenorphine (FDA-approved age 16+) with informed consent from his foster parent and DFCS case manager. He attends adolescent IOP three times per week with family involvement (foster parent and biological mother where appropriate under reunification plan). He has co-occurring depression and is on sertraline. His confidentiality is protected under 42 CFR Part 2 and Georgia minor consent law. His Amerigroup care manager coordinates between his pediatrician, child psychiatrist, IOP therapist, foster parent, and DFCS case manager.

Diane, 55, Athens: AUD + ABD Medicaid + 1115 residential + acamprosate

Diane has alcohol use disorder of many years duration. She has compensated cirrhosis. Her ABD Medicaid covers her care. She completed inpatient detox at a Level 4 facility (Athens Regional Medical Center for medically managed withdrawal) followed by Level 3.5 residential treatment at a community provider under Georgia's 1115 SUD IMD demonstration. She transitioned to IOP at an Athens-area CSB and now outpatient with monthly visits. She is on acamprosate (Campral) at the FDA-labeled dose and attends weekly AA meetings (community-based, not Medicaid-billable). Her liver function is improving on continued abstinence. Her primary care addresses cirrhosis management with hepatology follow-up.

Antoine, 35, Augusta: Stimulant use disorder + contingency management + Oxford House

Antoine has methamphetamine use disorder. No FDA-approved medication exists for stimulant use disorder, so his treatment is behavioral and contingency-management-based. He participates in intensive outpatient treatment with weekly individual counseling, group therapy, contingency management (small monetary incentives for negative drug tests, the most evidence-based intervention for stimulant use disorder), and cognitive behavioral therapy. His ABD Medicaid covers all services. He lives in an Oxford House (peer-led sober living): his rent is his own responsibility paid from his SSI income, but his SUD treatment is Medicaid-covered. He attends Crystal Meth Anonymous as community support. Several months into treatment, he has been abstinent the longest stretch of his life.

Putting it together

Substance use disorder treatment under Georgia Medicaid has been substantially reshaped over the past decade. The SUPPORT Act of 2018 created the statutory IMD exception that opened the door to residential treatment coverage; the MATE Act of 2022 eliminated the X-waiver and dramatically expanded prescriber availability for buprenorphine; the Section 1115 reentry demonstration addresses the catastrophic overdose risk at the carceral-community transition; and the CCBHC demonstration is building integrated mental health and SUD capacity across Georgia.

What remains is the persistent gap between policy and practice. Georgia carries a substantial burden of diagnosable SUD; consult SAMHSA NSDUH state estimates for current state-level prevalence. Even with Pathways to Coverage, ABD Medicaid, pregnancy Medicaid, foster care Medicaid, and former-foster-youth Medicaid combined, only a fraction of affected Georgians are in active treatment. The federal framework now supports the treatment they need; the limiting factors are workforce capacity (especially in rural Georgia), stigma, and the practical realities of building a treatment relationship strong enough to support recovery.

For the families and individuals navigating this system, the most important practical points are these. First, naloxone is covered without prior authorization at no out-of-pocket cost and is also available OTC at any pharmacy. Second, buprenorphine is now available through any DEA-registered prescriber, including primary care, so the long-standing barrier of finding an X-waivered physician no longer applies. Third, 988 and GCAL at 1-800-715-4225 are 24/7 access points for crisis or treatment linkage. Fourth, pregnancy carries no penalty for SUD: Medicaid covers treatment, MOUD is recommended in pregnancy, and POSC supports rather than triggers child welfare. Fifth, the pre-release reentry coverage means individuals leaving Georgia incarceration can begin or continue MOUD with community linkage before release. Brevy covers related Georgia Medicaid topics including pharmacy benefit, behavioral health coverage, pregnancy coverage, and incarceration suspension in companion guides.

What to do next

If you or someone you love needs substance use disorder treatment in Georgia, the following contacts can help.

Crisis and immediate help Georgia Crisis and Access Line (GCAL): 1-800-715-4225 (24/7) 988 Suicide and Crisis Lifeline: dial or text 988 (24/7) SAMHSA National Helpline: 1-800-662-HELP (4357) (24/7)

Georgia Medicaid (DCH) Member Services: 1-866-211-0950 Online: dch.georgia.gov

Georgia DBHDD Provider Help Desk: 1-404-657-2252 General information: dbhdd.georgia.gov

Behavioral health through your CMO Amerigroup Behavioral Health: 1-800-600-4441 Peach State Behavioral Health: 1-800-704-1484 CareSource Behavioral Health: 1-855-202-0729 WellCare Behavioral Health: 1-866-231-1821

Naloxone and overdose prevention GA Overdose Prevention: 1-404-657-2300 GA Naloxone Standing Order info (DPH): 1-404-657-2700

Recovery and advocacy Georgia Council on Substance Abuse: 1-404-712-3000 Georgia Recovery Community Organization: 1-770-322-0080

Prescription monitoring GA Prescription Drug Monitoring Program Help Desk: 1-855-217-0117

This article is for general informational purposes only and does not constitute legal, medical, or financial advice. Coverage policies and program rules change. Verify with the Georgia Department of Community Health, DBHDD, or your CMO before making decisions. Visit brevy.com for additional Georgia Medicaid guides covering related behavioral health, pharmacy, and eligibility topics.

Find personalized help navigating Georgia at brevy.com.